【摘要】：正隨著分子生物學技術(shù)的廣泛應(yīng)用,腫瘤的分子檢測與臨床靶向用藥為患者提供新的治療。目前,肺癌已進入精準治療時代,方案及藥物的選擇是根據(jù)其組織學亞型和分子學檢測結(jié)果共同制定[1]。近年以表皮生長因子受體(epidermal growth factor receptor,EGFR)為靶點的分子靶向治療已成為非小細胞肺癌(non-small cell lung cancer,NSCLC)的治療方案,然而只有約1/3的患者存在EGFR敏感突變位點,對EG-
[Abstract]:With the wide application of molecular biology technology, tumor molecular detection and clinical targeting drugs provide new treatment for patients. At present, lung cancer has entered the era of accurate treatment, and the choice of schemes and drugs is based on the results of histologic subtypes and molecular tests [1]. In recent years, molecular targeted therapy targeting epidermis growth factor receptor (epidermal growth factor receptor,EGFR has become a treatment for non-small cell lung cancer (non-small cell lung cancer,NSCLC). However, only about 1 鈮，

本文編號：2509743